New study tracks Nintedanib's Long-Term effects on scleroderma lung disease
NCT ID NCT07080125
First seen Dec 08, 2025 · Last updated Apr 28, 2026 · Updated 18 times
Summary
This study follows 2,000 people with systemic sclerosis (scleroderma) who have lung scarring (interstitial lung disease) and are taking nintedanib. Researchers want to see how the drug affects lung function, quality of life, and survival over time. Participants are already part of a European registry and will visit their doctor yearly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EUSTAR Registry
Basel, 4051, Switzerland
Conditions
Explore the condition pages connected to this study.